Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €40.30 EUR
Change Today +1.83 / 4.76%
Volume 1.6M
GRF On Other Exchanges
Symbol
Exchange
OTC US
OTC US
NASDAQ GS
OTC US
Mexico
Continuous
Continuous
Frankfurt
Frankfurt
As of 11:38 AM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

grifols sa (GRF) Snapshot

Open
€39.25
Previous Close
€38.47
Day High
€40.77
Day Low
€38.96
52 Week High
04/15/15 - €42.90
52 Week Low
10/16/14 - €27.91
Market Cap
12.5B
Average Volume 10 Days
1.3M
EPS TTM
€1.48
Shares Outstanding
213.1M
EX-Date
06/8/15
P/E TM
27.2x
Dividend
€0.55
Dividend Yield
1.36%
Current Stock Chart for GRIFOLS SA (GRF)

Related News

No related news articles were found.

grifols sa (GRF) Related Businessweek News

No Related Businessweek News Found

grifols sa (GRF) Details

Grifols, S.A., a specialty biopharmaceutical company, develops, manufactures, and distributes plasma derivative products in the United States, Canada, Spain, rest of the European Union, and internationally. It specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation, and reagents for use in hospitals and clinics. The company operates through four segments: Bioscience, Diagnostic, Hospital, and Raw Materials and Others. The Bioscience segment manufactures plasma derivatives for therapeutic use, including the reception, analysis, quarantine, classification, fractionation, and purification of plasma; and sells and distributes end products. It offers plasma products, which include IVIG, Factor VIII, A1PI, and albumin; and intramuscular immunoglobulins, ATIII, Factor IX, and plasma thromboplastin components. The Diagnostic segment focuses on researching, developing, manufacturing, and marketing in vitro diagnostics products, including analytical instruments, reagents, and software for use in diagnostic and blood bank laboratories. It serves blood donation centers, clinical analysis laboratories, and hospital immunohematology services. The Hospital segment manufactures and installs products used by and in hospitals, such as parenteral solutions, and enteral and parenteral nutritional fluids. The Raw Materials and Others segment sells intermediate biological products; and renders manufacturing services to third party companies. The company also offers engineering services. Its products and services are used by healthcare providers to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases, and other medical conditions. The company serves hospitals and clinics, group purchasing organizations, governments, and other distributors through sales representatives, marketing partners, and third-party distributors. Grifols, S.A. was founded in 1940 and is headquartered in Barcelona, Spain.

13,993 Employees
Last Reported Date: 02/26/15
Founded in 1940

grifols sa (GRF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

grifols sa (GRF) Key Developments

Grifols, S.A. Jointly with Ortho Clinical Diagnostics Enter into Restated and Extended Contract with Abbott for Production of Current Antigens in Addition to Five New Ones in its Manufacturing Facility in Emeryville, California

Grifols, S.A. announced that it has signed, jointly with Ortho Clinical Diagnostics, a restated and extended contract through 2026 with Abbott for the production of current antigens in addition to five new ones in its manufacturing facility in Emeryville, California. The new contract, which extends manufacturing services through 2026, has a total value approximating $700 million. The new facility for the manufacture of recombinant antigens utilized in clinical diagnosis and blood screening, dubbed Project Horizon, is expected to be completed and licensed by the beginning of 2017. Until the new facility is completed and licensed, the antigens will continue to be produced in Grifols’ existing manufacturing facility in Emeryville.

Grifols, S.A. to Report First Half, 2015 Results on Jul 30, 2015

Grifols, S.A. announced that they will report first half, 2015 results on Jul 30, 2015

Grifols, S.A. - Shareholder/Analyst Call

Grifols, S.A. - Shareholder/Analyst Call

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GRF:SM €40.30 EUR +1.83

GRF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bio-Rad Laboratories Inc $150.81 USD +0.35
Endo International PLC $85.96 USD -0.23
H Lundbeck A/S kr159.80 DKK -0.10
Hospira Inc $89.40 USD -0.02
UCB SA €67.00 EUR +0.16
View Industry Companies
 

Industry Analysis

GRF

Industry Average

Valuation GRF Industry Range
Price/Earnings 28.1x
Price/Sales 3.8x
Price/Book 4.3x
Price/Cash Flow 17.6x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GRIFOLS SA, please visit www.grifols.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.